New antimalarial drugs 2019
Here are some new antimalarial drugs that were approved or in development in 2019:
- Tafenoquine (Krintafel): Approved by the FDA in August 2019, tafenoquine is a single-dose oral medication used to prevent malaria in patients 16 years of age and older. It is the first FDA-approved single-dose oral medication for the prevention of malaria.
- Falepiro (Falepiro): In development by GlaxoSmithKline, falepiro is a new antimalarial drug that has shown promising results in clinical trials. It is a dihydroorotate dehydrogenase (DHODH) inhibitor, which works by blocking the parasite's ability to synthesize pyrimidine nucleotides.
- OZ439 (OZ439): Developed by the Medicines for Malaria Venture (MMV), OZ439 is a new antimalarial drug that has shown high efficacy against multidrug-resistant malaria parasites. It is a dihydroartemisinin-piperaquine combination therapy that has been tested in several clinical trials.
- GSK333 (GSK333): In development by GlaxoSmithKline, GSK333 is a new antimalarial drug that targets the parasite's ability to synthesize fatty acids. It has shown promising results in preclinical studies and is being tested in clinical trials.
- MMV390048 (MMV390048): Developed by the Medicines for Malaria Venture (MMV), MMV390048 is a new antimalarial drug that targets the parasite's ability to synthesize pyrimidine nucleotides. It has shown high efficacy against multidrug-resistant malaria parasites and is being tested in clinical trials.
- Cipargamin (Cipargamin): In development by the University of California, San Francisco, cipargamin is a new antimalarial drug that targets the parasite's ability to synthesize amino acids. It has shown promising results in preclinical studies and is being tested in clinical trials.
- NITD609 (NITD609): Developed by the National Institute of Allergy and Infectious Diseases (NIAID), NITD609 is a new antimalarial drug that targets the parasite's ability to synthesize fatty acids. It has shown promising results in preclinical studies and is being tested in clinical trials.
These are just a few examples of new antimalarial drugs that were in development or approved in 2019. There are many more in the pipeline, and researchers continue to work on developing new and effective treatments for malaria.